WATERTOWN, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) today announced the closing
of its initial public offering of 6,900,000 shares of common stock,
including 900,000 shares of common stock issued upon the exercise in
full by the underwriters of their option to purchase additional shares,
at a public offering price of $15.00 per share, before underwriting
discounts. The aggregate net proceeds to Dicerna, after deducting
underwriting discounts and commissions and estimated offering expenses,
will be approximately $92.9 million.
Jefferies LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company,
Incorporated acted as joint book-running managers for the offering.
Robert W. Baird & Co. Incorporated acted as co-lead manager for the
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on January 29, 2014.
The offering was made only by means of a prospectus. A copy of the final
prospectus dated as of January 29, 2014 relating to these securities was
filed with the SEC and may be obtained from Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor,
New York, NY 10022, or by email at Prospectus_Department@Jefferies.com,
or by phone at 877-547-6340; Leerink Partners LLC, Attention: Syndicate
Department, One Federal Street, 37th Floor, Boston, MA 02110, or by
email at Syndicate@Leerink.com,
or by phone at 800-808-7525; or Stifel, Nicolaus & Company,
Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700,
San Francisco, CA 94104, or by phone at 405-364-2720.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About Dicerna Pharmaceuticals, Inc.
Dicerna is a biopharmaceutical company focused on the discovery and
development of innovative treatments for rare inherited diseases
involving the liver and for cancers that are genetically defined.
Dicerna is using its proprietary RNA interference (RNAi) technology
platform to build a broad pipeline in these therapeutic areas and
intends to discover, develop and commercialize novel therapeutics either
on its own or in collaboration with pharmaceutical partners.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statements. Applicable risks and uncertainties include
those identified under the heading "Risk Factors" included in the
prospectus related to the initial public offering, and in other filings
that Dicerna may make with the SEC in the future. The forward-looking
statements contained in this press release reflect Dicerna's current
views with respect to future events, and Dicerna does not undertake and
specifically disclaims any obligation to update any forward-looking
Dicerna Pharmaceuticals, Inc.
James E. Dentzer,
Chief Financial Officer
Chris Erdman, 781-235-3060
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media